QX008N
QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Human
|
IL7R |
QX008N binds human TSLP with a high affinity (Kd = 0.0175 nM) that is superior to the Tezepelumab (HY-P99366A) analog[1].
QX008N (2 μg/mL initial concentration, 1:5 gradient dilutions) specifically binds human, cynomolgus monkey, and rhesus macaque TSLP[1].
QX008N potently inhibits the interaction between human TSLP and the TSLPR-IL-7Rα complex[1].
QX008N (2 μg/mL initial concentration, 1:3 gradient dilutions) potently neutralizes TSLP-induced JAK/STAT signaling in SW756-STAT5-Luciferase cells exposed to recombinant human, natural human, or recombinant cynomolgus monkey TSLP[1].
QX008N (10 concentration points via 1:5 gradient dilutions) potently inhibits human TSLP-induced CCL17 secretion in human PBMCs (IC50 = 9.836 ng/mL) and whole blood (IC50 = 1.599 ng/mL), and CCL22 secretion in human PBMCs, with activity superior to the Tezepelumab analog[1].
QX008N, when combined with anti-IL-4R antibody Oturkibart (HY-P991152), potently inhibits CCL17 production in human PBMCs stimulated with TSLP, IL-4, IL-13, and IL-33, achieving 95.5% inhibition that exceeds the additive effect of monotherapies[1].
QX008N (6 day incubation), when combined with anti-IL-4R antibody QX005N, enhances inhibition of OVA-induced CCL17, IL-5, and CCL26 production in a ternary culture model of MRC-5 fibroblasts, A549 epithelial cells, and human PBMCs, compared to QX008N monotherapy[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Cynomolgus monkey (male, 3-6 years, 2.5-7.0 kg, sensitized via intraperitoneal injection of Ascaris suis extract mixed with Al(OH)3 adjuvant at weeks 1, 2, and 3, followed by nebulized allergen challenge at weeks 4-7)[1]
-
Dosage:10 mg/kg; 50 mg/kg
-
Administration:once weekly; 6 doses; subcutaneous injection
-
Result:Decreased percentage change in airway resistance by 25% and increased percentage change in lung dynamic compliance by 20% at one week after three 10 mg/kg doses.
Reduced peripheral blood specific IgE by ~38% after three 10 mg/kg doses and TSLP by ~42% after six 10 mg/kg doses.
Decreased percentage change in airway resistance by 42.4% and increased percentage change in lung dynamic compliance by 30% at one week after first 50 mg/kg dose.
Reduced peripheral blood TSLP by ~66% and specific IgE by ~62% after first 50 mg/kg dose.
Lowered TSLP levels, eosinophil counts and eosinophil percentage in bronchoalveolar lavage fluid at 10 mg/kg and 50 mg/kg.
Attenuated eosinophil infiltration in lung tissue at 10 mg/kg and 50 mg/kg.
Reached plasma concentration of 336.3 μg/mL after first 50 mg/kg dose.
Q969D9-1
TSLP
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Product Image
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
QX008N Related Classifications
HY-P992447 Related Classifications
Powered by Bioz